Category News

FDA Grants Revolution Medicines Priority Voucher for Daraxonrasib (RMC-6236)

Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Under Commissioner’s National Priority Voucher Pilot Program Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company pioneering the development of targeted therapies…

Read MoreFDA Grants Revolution Medicines Priority Voucher for Daraxonrasib (RMC-6236)

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement for the development, manufacturing, and commercialization of…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

SelectQuote Research Reveals Critical Gaps in Healthcare, Urges Personalized Solutions

SelectQuote Research Reveals Critical Gaps in Medicare Care, Underscoring Need for Personalized Healthcare Solutions OVERLAND PARK, Kan.–(BUSINESS WIRE)–SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and the owner of a rapidly expanding healthcare services platform, today published…

Read MoreSelectQuote Research Reveals Critical Gaps in Healthcare, Urges Personalized Solutions